Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

November 2015

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, empagliflozin (Jardiance).

Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes.

But new evidence suggests empagliflozin also reduces CV risk.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Sepsis Wait to Renally Adjust Antibiotics in Severely Septic Patients
Diabetes Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon
Diabetes Reassure Patients that NPH and Regular are Safe and Effective
Aspirin Assess Aspirin Need Before Discharge
Pediatrics Watch for Tramadol Toxicity in Children
Practice Review PDMP for Newly Admitted Patients
Chronic Pain Use a Stepwise Approach to Managing Neuropathic Pain
Vaccines Develop a System to Know Which Pneumococcal Vaccine to Give at Discharge
Psychiatry Update Enrollment in the New Clozapine REMS Program
Cardiology Reassure Heparin is Safe and Effective in the Cath Lab
Med Safety Use 1 mg/mL Instead of 1:1000 for Safer Epinephrine Prescribing